{
    "clinical_study": {
        "@rank": "80616", 
        "arm_group": [
            {
                "arm_group_label": "Sildenafil", 
                "arm_group_type": "Experimental", 
                "description": "Sildenafil 20 mg"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the safety and clinical efficacy of HGP1207\n      (Sildenafil) in subjects with pulmonary hypertension associated with systolic heart failure."
        }, 
        "brief_title": "Safety and Efficacy Study of HGP1207 in Patients With Pulmonary Hypertension", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Pulmonary Hypertension", 
            "Systolic Dysfunction"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hypertension", 
                "Hypertension, Pulmonary", 
                "Heart Failure, Systolic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with a diagnosis of chronic heart failure (NYHA Class II and III)\n\n          -  LVEF \u2264 40%\n\n          -  Elevated systolic PAP: \u2265 40 mmHg\n\n          -  Patients must be treated with an ACE inhibitor, ARB, beta-blocker, aldosterone\n             antagonist at a stable dose for at least 4 weeks prior to visit 1\n\n        Exclusion Criteria:\n\n          -  Patients with pulmonary hypertension associated with chronic obstructive pulmonary\n             disease, interstitial lung disease, chronic thromboembolism or unclear/multifactorial\n             mechanisms\n\n          -  Patients who have received Nitrates/NO donor or Cytochrome P450 3A4 inhibitors within\n             30 days prior to visit 1\n\n          -  Patients who have received calcium channel blocker, endothelin receptor antagonist,\n             prostacyclin analogues, phosphodiesterase 5 inhibitors within 90 days prior to visit\n             1\n\n          -  History of hypersensitivity or allergy to sildenafil or any excipients of its\n             formulation\n\n          -  Patients with hypertension (sitSBP >170 mmHg or sitDBP>100 mmHg) or hypotension\n             (sitSBP<90 mmHg or sitDBP<50 mmHg)\n\n          -  Patients with other medical condition (i.e.,alcoholism, drug abuse) that may cause\n             the patient to be non-compliant with the protocol, confound the data interpretation\n\n          -  Pregnant females or those of child bearing potential who have not had a negative\n             pregnancy test"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "144", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01913847", 
            "org_study_id": "HM-SIL-301"
        }, 
        "intervention": [
            {
                "arm_group_label": "Sildenafil", 
                "description": "Oral sildenafil 20 mg TID for 12 weeks", 
                "intervention_name": "Sildenafil", 
                "intervention_type": "Drug", 
                "other_name": [
                    "HGP1207", 
                    "PAHTENSION chewable tablet"
                ]
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Oral placebo TID for 12 weeks", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sildenafil"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 30, 2013", 
        "location": {
            "contact": {
                "email": "sokei@hanmail.net", 
                "last_name": "Ok", 
                "phone": "82-31-8086-2538"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "11 institutions including Hallym University Dongtan Sacred Heart Hospital"
            }, 
            "investigator": {
                "last_name": "Kyu Hyung Ryu, M.D. Ph.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase III Study to Evaluate Efficacy and Safety of HGP1207 in Patients With Pulmonary Hypertension Associated With Systolic Heart Failure", 
        "overall_contact": {
            "email": "freedude@hanmi.co.kr", 
            "last_name": "Kwon"
        }, 
        "overall_contact_backup": {
            "email": "hanhs@hanmi.co.kr", 
            "last_name": "Han"
        }, 
        "overall_official": {
            "affiliation": "Hallym University Dongtan Sacred Heart Hospital", 
            "last_name": "Kyu Hyung Ryu, M.D. Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in 6-min-walk test distance", 
            "safety_issue": "No", 
            "time_frame": "at 12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01913847"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in 6-min-walk test distance", 
                "safety_issue": "No", 
                "time_frame": "at 6 weeks"
            }, 
            {
                "measure": "Change from baseline in systolic pulmonary arterial pressure (PAP)", 
                "safety_issue": "No", 
                "time_frame": "at 6 weeks and 12 weeks"
            }, 
            {
                "measure": "Change from baseline in [NT pro-BNP]", 
                "safety_issue": "No", 
                "time_frame": "at 6 weeks and 12 weeks"
            }, 
            {
                "measure": "Improvement in NYHA functional class", 
                "safety_issue": "No", 
                "time_frame": "at 6 weeks and 12 weeks"
            }, 
            {
                "measure": "Quality of life (QoL) assessed by EuroQoL(EQ-5D-3L) and EQ visual analogue scales (VAS)", 
                "safety_issue": "Yes", 
                "time_frame": "at 6 weeks and 12 weeks"
            }, 
            {
                "measure": "Delaying time to first occurrence of either cardiovascular events", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Hanmi Pharmaceutical Company Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hanmi Pharmaceutical Company Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}